Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced two new appointments to its...
August 02, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second...
June 06, 2023 16:35 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

VANCOUVER, British Columbia, June 06, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
May 31, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference

VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
May 11, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference

VANCOUVER, British Columbia, May 11, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
May 09, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

XEN1101 Phase 3 epilepsy program continues to make significant progress across all ongoing clinical trials including the recent initiation of X-TOLE3 in addition to the ongoing X-TOLE2 and X-ACKT...
May 03, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023

VANCOUVER, British Columbia, May 03, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
May 02, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update

VANCOUVER, British Columbia, May 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its first...
April 24, 2023 08:00 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting

Oral presentation by Dr. Jacqueline French to outline sustained monthly reduction in focal onset seizures during open-label extension of X-TOLE study Poster to present the trial design for Phase 3...
April 21, 2023 16:01 ET | Source: Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

BURNABY, British Columbia, April 21, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will host a company...